Press Release Archives - MOMA Therapeutics

MOMA Therapeutics Appoints Marc Ballas, M.D., as Head of Clinical Development, and Adam Thomas as Chief People & Experience Officer

CAMBRIDGE, Mass., June 25, 2024— MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced the…

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer CAMBRIDGE, Mass., March 11, 2024 – MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation…

MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies

CAMBRIDGE, Mass., January 4, 2024 – MOMA Therapeutics, a biotechnology company focused on identifying and targeting highly dynamic, difficult to drug targets in cancer and other diseases, is pleased to…

MOMA Therapeutics Appoints Industry Leader Jeff Albers as Chair of the Board of Directors

Company Announces Plans to Nominate Two Development Candidates in 2023, Tracking Toward FDA Investigational New Drug Applications in 2024 – CAMBRIDGE, Mass., February 8, 2023 – MOMA Therapeutics, a biopharmaceutical…

MOMA Therapeutics Announces $150 Million Series B Financing

Proceeds to fund the advancement of multiple precision oncology programs toward the clinic Financing led by Goldman Sachs Asset Management and includes multiple leading healthcare funds CAMBRIDGE, Mass., May 10,…

MOMA Therapeutics Appoints Hans Bitter, Ph.D., as Senior Vice President and Head, Data Science

Company Expands Leadership Team with Appointment of Nazareth Martinez Shedden as Vice President, Strategic Finance CAMBRIDGE, Mass., October 5, 2021 – MOMA Therapeutics, a biopharmaceutical company discovering the next generation…

Fierce Biotech names MOMA Therapeutics as one of its “Fierce 15” Biotech Companies of 2021

Fierce Biotech names MOMA Therapeutics as one of its “Fierce 15” Biotech Companies of 2021 Cambridge, MA – September 27, 2021 – MOMA Therapeutics today announced that Fierce Biotech has…

MOMA Therapeutics Appoints Semi Trotto as Chief People and Experience Officer

CAMBRIDGE, Mass., September 8, 2021 – MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Semi…

MOMA Therapeutics Appoints Peter Hammerman, M.D., Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., May 3, 2021 – MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Peter…

MOMA Therapeutics Appoints Asit Parikh, M.D., Ph.D. as President and Chief Executive Officer

CAMBRIDGE, Mass., February 1, 2021 – MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Asit…